Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Raises $40M in Series D Financing Round

NEW YORK (GenomeWeb) – Epic Sciences said today that it has completed a $40 million Series D financing.

Hermed Capital led the round, which also included Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures.

Epic said it plans to use the funds to accelerate clinical validation of its pipeline of oncology tests, which is led by the firm's AR-v7 prostate cancer assay, now being commercialized in partnership with Genomic Health as OncotypeDx AR-V7 Nucleus Detect.

The money will also help Epic work to enhance its proprietary "No Cell Left Behind" technology to include characterization of rare leukocyte cell populations using digital imaging and big data analytics, the firm said. The company hopes this will allow the platform to glean insights into the cellular drivers of response or resistance to new therapeutics like cancer immunotherapies.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.